Rebecca Wilson
WE Buchan
Hello, everyone, and welcome to today’s webinar unlocking sustainable clinical trials growth, which is part of the Cogstate Investor Insight series. I’m pleased to introduce our panelists today, Brad O’Connor, CEO and Managing Director; Rachel Colite, our Executive VP of Clinical Trials; Paul Maruff, Chief Innovation Officer; and Luka Lucic, Senior Director, Clinical Science of Psychiatry.
Before we begin, please note this presentation has been prepared by Cogstate for general information only. It is not intended to be complete, is not financial product advice and includes forward-looking statements that are subject to assumptions, risks and uncertainties. You should consider your own circumstances and seek independent professional advice if needed. To that extent, permitted by law, Cogstate does not give any warranty as to the accuracy, completeness or reliability of the information and disclaims liability for any loss arising from reliance on it. Also, a reminder that this webinar is being recorded. [Operator Instructions]
I’d like to now hand over to you, Brad.
Bradley O’Connor
CEO, MD & Executive Director
Thank you, Beck. Welcome, everybody. This is one of the series of these webinars we have done. For those who have missed the others, you can see them on the Investors section of the Cogstate website. We started with an interview with Anthony Costello, who is the CEO of Medidata. We’ve done some deep dive into Alzheimer’s disease. And today, we’re going to deep dive into some other indications and really around the thematic of how is Cogstate winning
